Increased Cytokine-Induced Cytotoxicity of Pancreatic Islet Cells from Transgenic Mice Expressing the Src-like Tyrosine Kinase GTK

Cecilia Annerén and Michael Welsh
Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
Contributed by D.F. Steiner. Accepted January 31, 2001

Abstract

Background: The loss of β cells in type 1 diabetes may involve protein kinases because they control cell growth, differentiation, and survival. Previous studies have revealed that GTK, a Src-like protein tyrosine kinase expressed in β cells (also named Bsk/Iyk), regulates multiple responses including growth and survival of rat insulinoma cells (RINm5F) and differentiation of neuronal PC12 cells. In the present study, we have generated a transgenic mouse expressing a kinase active GTK mutant (GTK-Y504F) under the control of the rat insulin 1 promoter to establish a role of GTK in β cells.

Materials and Methods: Control and GTK-transgenic CBA mice were used for determination of in vivo glucose tolerance and the relative insulin-positive area. Isolated islets from both groups were cultured in the absence and presence of cytokines and insulin secretion, viability, and protein expression were assessed.

Results: The β-cell mass of GTK-transgenic mice was increased as a consequence of a larger pancreas and an increased relative β-cell area. Islets isolated from the transgenic animals exhibited an enhanced glucose-induced insulin release and reduced viability in response to cytokines that could not be explained by higher levels of nitric oxide (NO) compared with control islets. Extracellular signal-regulated kinase (ERK) 1/2, p38 mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK), and Akt were all activated by cytokines, but GTK-transgenic islets contained higher basal levels of phosphorylated ERK1/2 and lower basal levels of phosphorylated p38 compared with the control islets. The total amount of activated MAPKs was, however, higher in the cytokine-stimulated transgenic islets compared with the control islets due to increased levels of phospho-ERK1/2. Moreover, the proline-rich tyrosine kinase (PYK) 2 (also named RAFTK/CAK β/CADTK) levels were elevated in response to a 24-hr exposure to cytokines in control islets but not in the GTK-transgenic islets.

Conclusions: These results suggest that although GTK increases the β-cell mass, it also enhances islet cell death in response to cytokines and may thus be involved in the β-cell damage in type 1 diabetes.

Introduction

Type 1 diabetes (insulin-dependent diabetes mellitus [IDDM]) results from a selective destruction of the insulin-producing pancreatic β cells and a limited capacity for the remaining β cells to regenerate in a compensatory manner. Macrophages and lymphocytes infiltrate the pancreatic islets and secrete inflammatory products, such as cytokines and free radicals that are highly toxic to the β cells but not to the α cells (reviewed in [1–4]). It is presently clear that the active β-cell mass is a function of replication of preexisting β cells, β-cell neogenesis, and β-cell survival (5), and a significant amount of research has been conducted to elucidate the signaling pathways regulating each of these.

Interleukin (IL)-1β has been studied extensively as a cytokine secreted by the inflammatory macrophages present in the insulitis (for a review see Mandrup-Pulsen [6]). IL-1β alone or in combination with interferon (INF)-γ and/or tumor necrosis factor-alpha (TNF-α) induces DNA fragmentation, nuclear condensation, and death of pancreatic β cells, and these events are preceded by expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production (reviewed in [1,3,4,7]). However, some observations suggest that NO production is neither necessary nor sufficient for mediation of cytokine-induced β-cell destruction and blocking iNOS does not fully protect β cells from cytokine-mediated inhibition of insulin release or induction of apoptosis (8). Additional mediators of cytokine-induced β-cell death may therefore be necessary, such as the Fas/FasL (9–11) and the mitogen-activated protein kinase (MAPK) cascades, which includes extracellular signal-regulated kinase (ERK-1/2), JNK (c-Jun NH2-terminal kinase), and p38 MAPK (12–14).

IL-1 has recently been shown to activate and phosphorylate the anti-apoptotic protein kinase Akt/protein kinase B in astrocytes (15) and endothelial cells (16). The p85 subunit of phosphatidylinositol 3 (PI3)-kinase was shown to interact with IL-1β receptor accessory, leading to the...
of the p110 catalytic subunit and a subsequent phosphorylation of Akt (17). Several studies have shown that IL-1β-induced PI3-kinase activation causes phosphorylation and transactivation of NFκB (15,17,18), whereas one study suggests that the effects of the PI3-kinase/Akt pathway are independent of NFκB (16). To date, however, it has not been investigated whether IL-1β induces phosphorylation of Akt in β cells.

Protein tyrosine kinases play an important role in the regulation of growth, differentiation, and survival in all cells. In search of protein tyrosine kinases expressed in β cells, we identified GTK, a novel Src related kinase, which was subsequently cloned from the mouse βTC-1 cell line (19). We have in previous studies shown that Tyr-504 regulates GTK kinase activity and that mutation of this tyrosine to phenylalanine causes a 2- to 3-fold increase in GTK kinase activity (20). RINm5F cells expressing GTK(Y504F) exhibit a decreased proliferation rate and altered hormone mRNA levels as well as a reduced cell viability in response to cytokines (20). We have also observed that wild-type GTK expressed in the rat pheochromocytoma PC12 cell line induces NGF-independent neurite outgrowth (21), suggesting a role for GTK in cell differentiation. It thus appears that GTK is involved in signal transduction pathways regulating multiple responses including growth, differentiation and survival.

In the present study, we generated a transgenic mouse expressing a kinase active GTK-mutant (GTK-Y504F) under the control of the rat insulin I promoter to establish a role of GTK for β-cell function, growth, and survival.

Materials and Methods

Materials

Fetal calf serum (FCS) and penicillin/streptomycin solutions were purchased from HyClone Europe Ltd (Cramlington, UK). Phenylmethylsulfonylfluoride (PMSF) was from Sigma Chemical Co (St. Louis, MO, USA). Immobilon-P was from Millipore Corporation (Bedford, MA, USA), horse radish peroxidase linked donkey anti-rabbit or anti-mouse IgG, enhanced chemiluminescence (ECL) detection system; Rainbow Molecular Weight Standard and Hyperform were from Amersham Pharmacia Biotech (Uppsala, Sweden). GTK antiserum was made perfilm were from Amersham Pharmacia Biotech (Bedford, MA, USA), horse radish peroxidase linked donkey anti-rabbit or anti-mouse IgG, enhanced chemiluminescence (ECL) detection system; Rainbow Molecular Weight Standard and Hyperform were from Amersham Pharmacia Biotech (Uppsala, Sweden). GTK antiserum was made.

Southern blot analysis on DNA obtained from tail genome of the offspring was verified by PCR and Southern blot analysis on DNA obtained from tail samples from 3-week-old mice using a 5'-primer matching nucleotide 1502-1522 of the GTK cDNA (5′-GGTAGACATGGCGGCCACAGGT-3′) and a 3'-primer corresponding to the last 18 nucleotides of the myc-epitope (5′-TGAGATGAGTTTTGTTC-3′). One female mouse with insertion of the transgene was obtained and bred with a control CBA mouse and when male GTK-transgenic were born they were bred with GTK-transgenic female mice. The mice used were mainly heterozygous (at least 75%), but due to practical reasons and because there were no obvious differences in phenotype or GTK expression between homozygous and heterozygous mice we have not excluded animals being homozygous for the transgene. Transcription from the transgene was studied by RT-PCR on DNase-treated RNA from islets isolated from 3-month-old mice using the same primers as above. All animal experimentation was approved by the Institutional Review Board for Animal Experimentation.

Islet Isolation and Culture

Islets were isolated from control CBA or GTK transgenic 3- to 4-month-old mice of both genders by a collagenase digestion procedure (23) and cultured for 24 hr in RPMI 1640 + 10% FCS followed by incubation in the absence or presence of cytokines (50 U/ml of human IL-1β + 1000 U/ml of murine INF-γ) for the indicated time points. These concentrations of cytokines were selected based on previous studies using pancreatic islets (24). The islets were then used for determination of insulin secretion, insulin content, DNA content, apoptosis, or protein expression.

Insulin Release

Ten islets in triplets were transferred to multi-well plates containing 100 µl of KR Bah buffer (114.3 mM of NaCl, 4.74 mM of KCl, 1.15 mM of KH2PO4, 302 Molecular Medicine, Volume 7, Number 5, May 2001
1.18 mM of MgSO₄, 25 mM of NaHCO₃, 10.0 mM of HEPES, 4.26 mM of NaOH, and 2.54 mM of CaCl₂; pH 7.4) supplemented with 2 mg/ml of BSA and 1.7 mM of glucose and incubated for 60 min followed by an incubation for 60 min in 16.7 mM of glucose and the insulin secretion was determined. The islets were then pooled, homogenized in 200 μl of water, and used for analyzing DNA content and insulin content. Insulin was measured by radioimmunoassay (RIA) (25).

**Labeling Index and b-Cell Area**

Three-month-old mice were injected intraperitoneally with 1 mCi of [methyl-³H] thymidine/kg body weight 1.5 hr before the mice were killed. The pancreas was dissected, fixed in 10% formalin, and sectioned. The labeling index was determined by [³H] thymidine autoradiography (26) and the percentage of insulin-positive area relative to the total pancreas area was determined by staining sections for insulin using an unlabeled peroxidase-antiperoxidase technique (27). The insulin-positive area was determined by two blinded independent observers on three cross-sections from different regions (caput, corpus, and cauda) of each pancreas, using a computerized image analysis system for morphometry (MOP; Videoplan, Kontron Bildanalyse Munich, Germany). To assess if there was any difference in islet cell size, a grid was placed over the insulin-stained sections and the number of insulin-positive cells was divided by the insulin-positive area (number of squares).

**Glucose Homeostasis**

For glucose homeostasis, a glucose tolerance test was performed as follows. Male and female GTK transgenic and control CBA mice 3–4 months of age were injected intraperitoneally with 250 μl of 30% glucose, and blood glucose was determined (MediSense Pen Sensor; MediSense, Waltham, MA, USA) on blood samples collected from the tail immediately before the glucose injections and after 10, 30, 60, and 120 min.

**Cell Death and Western Blotting**

Islets were cultured for the indicated time points with or without the presence of cytokines. For cell death, islets were incubated in phosphate-buffered saline (PBS) containing 10 μg/ml of propidium iodide (PI) and 20 μg/ml of bisbenzamide (Hoechst 33342 stain) for 5 min at 37°C, washed in PBS and examined with fluorescence microscopy. The percentage of apoptotic-like and necrotic-like cells was determined by differential counting of PI-positive cells by a blinded independent observer. Necrotic-like and apoptotic-like cells were discriminated by the uptake of PI, appearance of cell nucleus, and size (28). For protein levels, 60 islets from each group were washed with cold PBS, briefly sonicated in SDS sample buffer (containing β-mercaptoethanol and 2 mM of PMSF), and subjected to Western blot analysis. The membranes were incubated with the indicated antibodies and the immunoreactivity was subsequently detected by ECL.

**Nitrite Production**

Medium from islets cultured for 24 hr in the presence or absence of cytokines was collected and nitrite formation was assessed as follows: 100 μl of medium was added to a mixture of 0.5% naphtylenediamine dihydrochloride, 5% sulfanilamide, and 25% H₃PO₄, and incubated for 5 min at room temperature. The absorbance was measured spectrophotometrically at 546 nm against a standard curve of sodium nitrite (29).

**Statistical Analysis**

The means ± SEM for the number of observations are given. Each observation is based on the value obtained from one animal or individual islet isolation. A blinded independent observer made the cell countings (labeling index and apoptosis) and the MOP analysis (β-cell area). Unpaired Student’s t test or, when appropriate, analysis of variance (ANOVA) followed by a multiple pairwise comparison procedure using the Student-Newman-Keuls method was used to determine the statistical differences between groups.

**Results**

**Expression of the Transgene**

Expression of the transgene was verified by PCR of the transgenic islet cDNA using a 3′primer matching the C-terminal myc-epitope. We could show that the GTK-Y504F mRNA is present in the transgenic mice only (Fig. 1A). To control that the obtained PCR product was amplified cDNA with no contamination of genomic DNA, samples that had not been treated with reverse transcriptase were run in parallel. Islets isolated from GTK-transgenic mice expressed only moderately elevated levels of the 57-kDa GTK protein (Fig. 1B) as determined by Western blot analysis of islet lysates or GTK immunoprecipitates using an unpurified GTK-reactive antibody (22).

**Pancreas Size, β-Cell Area, and Labeling Index**

The total pancreas of the GTK-transgenic mice was significantly larger and weighed in average almost 50 mg more. This was not solely due to an increase in body weight of the transgenic mice because the pancreas mass relative to the mouse body weight was significantly increased in the transgenic animals (Fig. 2A). When the mouse weight was plotted against the pancreas weight (Fig. 2A), the seven animals with the lowest pancreas weight were all confined to the CBA control group. The insulin-positive area relative the total pancreas area was also increased by at least 50% in the GTK transgenic (Fig. 2B). It might be argued that an increased β-cell area
is a consequence of hypertrophy of the islet cells; therefore, the number of insulin-producing cells divided by the corresponding islet area was counted. The obtained results, however, indicated that the observed increased \( \beta \)-cell area is a consequence of \( \beta \)-cell number rather than the \( \beta \)-cell size (results not shown). The increased \( \beta \)-cell mass in the GTK-transgenic mice is not due to an increased \( \beta \)-cell replication in the adult mice because the labeling index in vivo of the 3-month-old GTK transgenic was similar to that of control mice (Fig. 2B).

Insulin Content and Glucose-Stimulated Insulin Release

The relative stimulation of insulin release, measured as the release at high glucose (16.7 mM) divided by the release at low glucose (1.7 mM), was increased in the isolated GTK-transgenic islets compared with the corresponding control islets (Fig. 3A). The insulin release was more impaired by cytokine treatment (IL-1\( \beta \) and INF-\( \gamma \)) in the transgenic islets than it was in the control islets. Thus, the relative stimulation of insulin release was significantly decreased when the transgenic islets had been cultured with cytokines for 24 hr compared with the transgenic islets that had been cultured in the absence of cytokines (Fig. 3A). There was no difference in the islet insulin content per microgram DNA or insulin mRNA levels relative total mRNA, determined by RIA and Northern blotting for insulin and \( \beta \)-actin, respectively, between the groups (Table 1).

Glucose Homeostasis

To assess insulin release in vivo, glucose tolerance tests on male and female 3- to 5-month-old mice were performed. The basal blood glucose and the glucose disappearance rate after an intravenous injection of glucose were similar (Fig. 4). The blood glucose was increased to above 20 mM at 10 min after the injection in both groups and diminished rapidly, returning to near basal levels after 60 min.
previously (28). Islets from GTK-transgenic islets exhibited a significantly reduced viability, predominantly due to an increase in apoptosis-like cell death, in response to cytokines (50 U/ml of IL-1β + 1000 U/ml of INF-γ) compared with the control CBA islets (Fig. 5A). To see if the increased cytotoxicity was due to an induced production of NO, we measured the nitrite levels in the incubation medium as well as the expression of iNOS in response to cytokines. Cytokine treatment significantly increased NO formation to a similar degree in both groups (Fig. 5B). The expression of iNOS was also increased in islets treated with cytokines after 6 and 24 hr of exposure to cytokines, but there was no difference between transgenic and control islets (results not shown).

Cytokine-Induced Phosphorylation of p38, ERK1/2, JNK, and Akt

It has recently been shown that IL-1β induces phosphorylation and activation of the MAP kinases p38, ERK1/2, and JNK in insulin-producing cells (12–14, 30); therefore, the phosphorylation of these kinases was assessed after stimulation of isolated islets with cytokines for different time points. The relative ERK1/2 phosphorylation, measured as the amount of phosphorylated ERK1/2 relative to the total amount of ERK1/2 in the absence of cytokines was 2-fold higher in the GTK-transgenic islets compared with the control islets. Cytokine treatment for 1.5 hr doubled the phosphorylation of ERK1/2 in both groups, thus making the amount of phosphorylated ERK1/2 in response to cytokine treatment higher in the transgenic islets (Fig. 6A). At 6 and 24 hr with cytokines, the phosphorylation of ERK1/2 returned to basal levels in both groups.

The relative phosphorylation of p38 in the absence of cytokines was 50% lower in the GTK-transgenic islets. Cytokine treatment for 1.5 hr, however, increased the phosphorylation of p38 to nearly the same levels in both groups. Thus, cytokine treatment increased p38 phosphorylation three times in the control islets and six times in the GTK-transgenic islets. After a 6-hr stimulation, the p38 phosphorylation in the control cells returned to near basal levels, whereas the phosphorylation in the GTK cells was still three times higher than the basal level (Fig. 6B).

The relative JNK phosphorylation was similar in the GTK islets and control islets. Both groups had a low basal phosphorylation of JNK that increased 5-fold in response to a 1.5-hr stimulation, decreased to a 3-fold increase at 6 hr and returned to basal levels at 24 hr with cytokines (Fig. 6C).

Because IL-1β has been shown to activate and phosphorylate Akt in other cell types (15–17), we decided to investigate the phosphorylation in response to IL-1β and INF-γ in islets from control CBA mice and GTK-transgenic mice. We found that the relative phosphorylation of Akt is increased to the same extent in the control and GTK-transgenic islets.
islets treated with cytokines. The GTK-transgenic islets contained lower PYK2 levels in the basal state compared to the control, and the expression was not significantly affected by the cytokine treatment; thus, the transgenic islets contained about half the amount of PYK2 in the presence of cytokines compared with the control islets (Fig. 7B). We could not observe any significant changes in the FAK levels in response to cytokines, nor did we see any differences between the two groups (Fig. 7A).

**Discussion**

Protein tyrosine kinases play an important role in the regulation of numerous pathways, leading to disperse effects such as replication, migration, or cell death. We have previously shown that GTK, a cytoplasmic tyrosine kinase, is involved in signal transduction pathways controlling multiple responses including growth, differentiation, and survival (20–22). GTK is endogenously expressed in fetal and adult islets of Langerhans (19), but its function in these cells remains to be determined. To study PYK2 and FAK levels in response to cytokines in islets, we examined the expression in isolated islets cultured for 24 hr in the absence and presence of cytokines. The PYK2 levels were significantly elevated in the control islets treated with cytokines. The GTK-transgenic islets contained lower PYK2 levels in the basal state compared to the control, and the expression was not significantly affected by the cytokine treatment; thus, the transgenic islets contained about half the amount of PYK2 in the presence of cytokines compared with the control islets (Fig. 7B). We could not observe any significant changes in the FAK levels in response to cytokines, nor did we see any differences between the two groups (Fig. 7A).

**Table 1.** Insulin and DNA content of isolated islets from GTK-transgenic and CBA control mice

|        | IL-1β/INF-γ | DNA Content (µg/30 islets) | Insulin Content (µg/µg DNA) | Insulin mRNA Relative Levels |
|--------|-------------|-----------------------------|-------------------------------|-----------------------------|
| CBA control | -           | 0.72 ± 0.04                 | 900 ± 120                     | 1.9 ± 0.4                   |
| CBA control | +           | 0.64 ± 0.08                 | 1070 ± 200                    | n.d.                        |
| CBA-GTK  | -           | 0.64 ± 0.08                 | 1020 ± 125                    | 1.8 ± 0.3                   |
| CBA-GTK  | +           | 0.60 ± 0.08                 | 1070 ± 100                    | n.d.                        |

Ten islets in triplets were isolated from control or GTK-transgenic CBA mice of both genders, cultured in RPMI 1640 + 10% serum for 24 hr in the absence or presence of 1000 U/ml INF-γ and 50 U/ml IL-1β and used for insulin release (see Fig. 2). The islets were then pooled, homogenized in 200 µl of water and the insulin and DNA contents were measured. Values are mean ± SEM for 12 observations. Equal amounts of total RNA from 60 islets cultured for 24 hr in RPMI 1640 + 10% serum were run on a denaturing agarose gel and subjected to Northern blotting for insulin and β-actin. The relative insulin mRNA levels were determined by densitometry. Values are mean ± SEM for 10 observations; n.d., not determined.

![Fig. 4. Blood glucose profiles after an intravenous injection of glucose. (A) Male and female 3-month-old mice were given an intravenous injection of 250 µl of glucose (30%) and the plasma glucose levels were measured at the indicated time points. Data are mean ± SEM from 13 mice.](image)
dependent increase in \( \beta \)-cell mass results in elevated insulin secretion. Insulin is a potent growth factor known to induce proliferation through activation of mitogenic pathways such as the ERK1/2 pathway (reviewed in [32,33]). The relative insulin secretion in response to glucose in vitro was also slightly enhanced and appears to reflect both an absolute decrease in insulin release at low glucose levels and elevated secretion at high glucose.

The most obvious effect of GTK in \( \beta \) cells was the markedly reduced viability of the transgenic islets when cultured in the presence of cytokines. An almost 60% increase in islet cell death was observed in the GTK-transgenic group compared with the cytokine-treated control islets, and this was mainly due to an increase in apoptosis-like cell death. These findings are in line with a previous experiment in the insulinoma RINm5F cell line overexpressing Y504F-mutated GTK, in which the cytokine-induced cell death was increased by at least 70% compared with the control cells (20). It is well documented that within the time and dose window used in this study, cytokines exert a \( \beta \)-cell selective toxic effect (34); therefore, we did not discriminate between \( \beta \) cells and non-\( \beta \) cells when studying cytokine-induced cytotoxicity. Moreover, because the transgene is exclusively expressed in insulin-producing cells, the increased cytotoxicity observed in the transgenic islets is likely to occur in the \( \beta \) cells.

To study the mechanism behind the rise in cytokine-mediated death of the GTK-expressing cells, we looked at different pathways that have been suggested to play a role in mediating the cytotoxic effects of IL-1\( \beta \) and INF-\( \gamma \). We did not observe any difference in NO production or iNOS expression between the two groups, indicating that GTK mediates the increase in cytokine-induced cytotoxicity by a pathway independent of iNOS. Although NO has been proven to be an important second messenger for the cytotoxic effect of IL-1\( \beta \), NO alone does not seem to be sufficient to bring about this destruction. It has, for instance, been shown that FACS-purified \( \beta \) cells from iNOS-deficient mice are as susceptible to cytokine-induced apoptosis as the wild-type \( \beta \) cells (8).

IL-1\( \beta \) has recently been shown to induce activation of the three MAP/SAPKs p38, ERK1/2, and JNK to a larger extent in transformed and primary \( \beta \) cells (12–14) than in \( \alpha \) cells, and this response was not found to be associated with a more pronounced IL-1\( \beta \)-induced NO production. It was therefore suggested that an increased MAPK signaling in response to IL-1\( \beta \) represents a molecular marker of \( \beta \)-cell differentiation as well as a possible explanation for the increased susceptibility to cytokines (13). Our data demonstrate that ERK1/2, p38, and JNK are all activated by cytokines in mouse islets, and that the GTK-transgenic islets contain higher basal levels of phosphorylated ERK1/2 but lower basal levels of phosphorylated p38 compared with control.
islets. The total amount of phosphorylated MAP kinases was thus similar in the two groups in the absence of cytokines; the lower levels of p38 is compensated for by the elevated levels of ERK1/2. However, when the islets are stimulated with cytokines, the total amount of activated MAPKs is higher in the transgenic islets compared to the control islets owing to the increased levels of phosphorylated p38 and JNK. Could the increased MAPK activation observed in the GTK-transgenic islets be responsible for their increased sensitivity to cytokines? It is generally believed that activation of JNK and p38 MAP kinases is associated with promotion of apoptosis (reviewed in Cross et al. [35]) and specific JNK inhibitors have been shown to protect against IL-1β-induced apoptosis (13). However, the role of ERK1/2 in cytokine-induced cell death is more controversial, because ERK1/2 has been suggested to contribute to IL-1β-induced apoptosis in β cells (14) and NO-mediated cell death in macrophages (36), although ERK1/2 is generally believed to promote survival (37,38). To make this issue increasingly complicated, it has been shown that specific p38 and ERK1/2 inhibitors protect cells from IL-1β-induced NO production (12,14); however, this protection was less marked when the inhibitors were used together with a combination of IL-1β and INF-γ. Nevertheless, an overall induction of MAP kinase activation might be important for the increased sensitivity of the GTK-transgenic islets to the cytotoxic action of IL-1β and INF-γ, although other signaling pathways might be involved as well.

In this study, we also show for the first time that Akt is phosphorylated in response to cytokine treatment in pancreatic islet cells. It has previously been shown that IL-1 treatment reduces apoptosis caused by growth factor or serum withdrawal by activating the phosphatidyl inositol 3-kinase/Akt pathway in endothelial cells and astrocytes (15–18), and it has been suggested that this involves the activation of the transcription factor NFκB (15,17,18). The PI3-kinase/Akt pathway is most likely not involved in the altered viability of the GTK-expressing islets, however, because the activation of Akt caused by cytokines was equal in the two groups.

In the present study, we also show that the PYK2 levels increase in the control islets but not GTK-transgenic islets, following a 24-hr culture with cytokines. PYK2 has never before been studied in insulin-producing cells, but a recent study demonstrated that PYK2 participates in the antiviral response by INF-γ in fibroblast by activating the Jak2/Stat1 pathway (39). PYK2 is structurally related to FAK, which is generally believed to be involved in integrin signaling and survival (reviewed in Schlaepfer et al. [31]). Although PYK2 and FAK share many downstream effectors, accumulating reports are showing that PYK2 mediate signals via pathways distinct from those of FAK. It has, for ex-
panied with increased phosphorylation of the adaptor protein Shb and activation of the Rap1 pathway (21). Overexpression of Shb in PC12 cells has also been found to induce NGF-dependent neurite outgrowth as well as Rap1 activation (44,45), indicating that GTK signals to promote neurite outgrowth via Shb. Interestingly, transgenic mice expressing Shb under the control of the rat insulin promoter exhibit a phenotype very similar to the one observed in the GTK-transgenic mice (24). Thus, the Shb-transgene mice display an increased relative β-cell area, an enhanced stimulation of insulin release of isolated islets and a decreased islet cell viability in response to cytokines compared with the corresponding control. These observed similarities in combination with the results obtained in the PC12 cells suggest that GTK could signal via Shb to induce part of its effects in the GTK-transgenic mice.

In conclusion, the results presented in this study suggest that GTK has dual effects in the β cells; whereas GTK induces the β-cell mass by unknown mechanisms, it could also enhance islet cell death in response to cytokines and may thus contribute to the β-cell damage in type 1 diabetes.

Acknowledgments

We are grateful to Drs Helena Edlund and Ulf Ahlgren for help with generating the transgenic mice and to Ing-Britt Hallgren and Ing-Marie Mör sare for technical assistance. This work was supported by grants from the Juvenile Diabetes Foundation International, the Swedish Medical Research Council (31X-10822), the Swedish Diabetes Association, the Novo-Nordisk Foundation, and the Family Ernfors Fund.

References

1. Mauricio D, Mandrup-Poulsen T. (1998) Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes 47: 1537–1543.
2. Rabinovitch A, Suarez-Pinzon WL, Shi Y, Morgan AR, Bleackley RC. (1994) DNA fragmentation is an early event in cytokine-induced islet beta-cell destruction. Diabetologia 37: 733–738.
3. Rabinovitch A, Suarez-Pinzon WL. (1998) Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 55: 1139–1149.
4. Rabinovitch A. (1998) An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab. Rev. 14: 129–151.
5. Finegood DT, Scaglia L, Bonner-Weir S. (1995) Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44: 249–256.
6. Mandrup-Poulsen T. (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39: 1005–1029.
7. Eizirik DL, Flodstrom M, Karlens AE, Welsh N. (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetes 39: 875–890.
8. Liu D, Pavlovic D, Chen MC, Flodstrom M, Sandler S, Eizirik DL. (2000) Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 49: 1116–1122.
Acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. Endocrinology 137: 5694–5699.

27. Erlandsen SL, Parsons JA, Burke JP, Redick JA, Van Orden DE, Van Orden LS. (1975) A modification of the unlabeled antibody enzyme method using heterologous antiserum for the light microscopic and ultrastructural localization of insulin, glucagon, and growth hormone. J. Histochem. Cytochem. 23: 666–677.

28. Saldeen J. (2000) Cytokines induce both necrosis and apoptosis via a common Bcl-2- inhibitable pathway in rat insulin-producing cells. Endocrinology 141: 2003–2010.

29. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 126: 131–138.

30. Welsh N. (1996) Interleukin-1-beta-induced ceramide and diacylglycerol generation may lead to activation of the c-Jun NH2-terminal kinase and the transcription factor ATF2 in the insulin-producing cell line RINm5F. J. Biol. Chem. 271: 8307–8312.

31. Schlaepfer DD, Hauck CR, Sieg DJ. (1999) Signaling through focal adhesion kinase. Prog. Biophys. Mol. Biol. 71: 435–478.

32. Avruch J. (1998) Insulin signal transduction through protein kinase cascades. Mol. Cell Biochem. 182: 31–48.

33. Combettes-Souverain M, Issad T. (1998) Molecular basis of insulin action. Diabetes Metab. 24: 477–489.

34. Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen JH, Dinarello CA. (1987) Ultrastructural studies of time-course and cellular specificity of interleukin-1 mediated islet cytotoxicity. Acta. Pathol. Microbiol. Immunol. Scand. [C] 95: 55–63.

35. Cross TG, Scheel-Toeller N, Hennriches NV, Deacon E, Salomon M, Lord JM. (2000) Serine/threonine protein kinases and apoptosis. Exp. Cell Res. 256: 34–41.

36. Mohr S, McCormick TS, Lapetina EG. (1998) Macrophages resistant to endogenously generated nitric oxide-mediated apoptosis are hypersensitive to exogenously added nitric oxide donors: dichotomous apoptotic response independent of caspase 3 and reversal by the mitogen-activated protein kinase (MEK) inhibitor PD 98059. Proc. Natl. Acad. Sci. USA 95: 5045–5050.

37. Birkenkamp KU, Dokter WH, Esselink MT, Jonk LJ, Kruijer W, Vellenga E. (1999) A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation. Leukemia 13: 1037–1045.

38. Xia Z, Dickens M, Rainingaud J, Davis RJ, Greenberg ME. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326–1331.

39. Takaoka A, Tanaka N, Milani Y, et al. (1999) Protein tyrosine kinase Pyk2 mediates the Jak-dependent activation of MAPK and Stat1 in IFN-gamma, but not IFN-alpha, signaling. Embo J. 18: 2480–2488.

40. Xiong W, Parsons JT. (1997) Induction of apoptosis after expression of PYK2, a tyrosine kinase structurally related to focal adhesion kinase. J. Cell Biol. 139: 529–539.

41. Murasawa S, Matsubara H, Mori Y, et al. (2000) Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-terminal kinase. J. Biol. Chem. 275: 26856–26863.

42. Bandyopadhyay G, Sajan MP, Kanoh Y, et al. (2000) Glucose activates MAP kinase (ERK) through proline-rich tyrosine kinase-2 and the Glut1 glucose transporter. J. Biol. Chem. 275:40817–40826.

43. Pandey P, Avraham S, Kumar S, et al. (1999) Activation of p38 mitogen-activated protein kinase by PYK2-related adhesion focal tyrosine kinase-dependent mechanism. J. Biol. Chem. 274: 10140–10144.

44. Karlsson T, Kullander K, Welsh M. (1998) The Src homology 2 domain protein Shb binds to and growth factor-dependent differentiation signals in PC12 cells. Cell Growth Differ. 9: 757–766.

45. Lu L, Annerén C, Reedquist CA, Bos JL, Welsh M. (2000) NGF-Dependent neurite outgrowth in PC12 cells overexpressing the Src homology 2-domain protein Shb requires activation of the Rap1 pathway. Exp. Cell Res. 259: 370–377.